COPD Is/Is Not a Systemic Disease? (Record no. 60621)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 09174nam a22005053i 4500 |
| 001 - CONTROL NUMBER | |
| control field | EBC3019991 |
| 003 - CONTROL NUMBER IDENTIFIER | |
| control field | MiAaPQ |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20240729124130.0 |
| 006 - FIXED-LENGTH DATA ELEMENTS--ADDITIONAL MATERIAL CHARACTERISTICS | |
| fixed length control field | m o d | |
| 007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION | |
| fixed length control field | cr cnu|||||||| |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 240724s2009 xx o ||||0 eng d |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| International Standard Book Number | 9781616687229 |
| Qualifying information | (electronic bk.) |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| Canceled/invalid ISBN | 9781608760510 |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (MiAaPQ)EBC3019991 |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (Au-PeEL)EBL3019991 |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (CaPaEBR)ebr10674999 |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (OCoLC)923661713 |
| 040 ## - CATALOGING SOURCE | |
| Original cataloging agency | MiAaPQ |
| Language of cataloging | eng |
| Description conventions | rda |
| -- | pn |
| Transcribing agency | MiAaPQ |
| Modifying agency | MiAaPQ |
| 050 #4 - LIBRARY OF CONGRESS CALL NUMBER | |
| Classification number | RC776.O3 -- C67 2010eb |
| 082 0# - DEWEY DECIMAL CLASSIFICATION NUMBER | |
| Classification number | 616.2/4 |
| 100 1# - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Donner, Claudio F. |
| 245 10 - TITLE STATEMENT | |
| Title | COPD Is/Is Not a Systemic Disease? |
| 250 ## - EDITION STATEMENT | |
| Edition statement | 1st ed. |
| 264 #1 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Place of production, publication, distribution, manufacture | Hauppauge : |
| Name of producer, publisher, distributor, manufacturer | Nova Science Publishers, Incorporated, |
| Date of production, publication, distribution, manufacture, or copyright notice | 2009. |
| 264 #4 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Date of production, publication, distribution, manufacture, or copyright notice | ©2010. |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | 1 online resource (296 pages) |
| 336 ## - CONTENT TYPE | |
| Content type term | text |
| Content type code | txt |
| Source | rdacontent |
| 337 ## - MEDIA TYPE | |
| Media type term | computer |
| Media type code | c |
| Source | rdamedia |
| 338 ## - CARRIER TYPE | |
| Carrier type term | online resource |
| Carrier type code | cr |
| Source | rdacarrier |
| 490 1# - SERIES STATEMENT | |
| Series statement | Public Health in the 21st Century |
| 505 0# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | Intro -- COPD IS/IS NOT A SYSTEMIC DISEASE? -- COPD IS/IS NOT A SYSTEMIC DISEASE? -- CONTENTS -- INTRODUCTION -- Chapter 1 COPD IS A SYSTEMIC DISEASE - THE PATHPHYSIOLOGICAL BASIS -- ABSTRACT -- INTRODUCTION -- Systemic Inflammation -- Genetics and Epigenetics -- Vascular Abnormalities -- Immunology -- Repair Failure -- Infections -- CONCLUSION -- REFERENCES -- Chapter 2 COPD IS NOT A SYSTEMIC DISEASE - THE PATHOPHYSIOLOGICAL BASIS -- ABSTRACT -- INTRODUCTION -- DIAGNOSIS AND STAGING OF COPD -- PATHOPHYSIOLOGY -- Small Airways Disease -- Pulmonary Hyperinflation -- Ventilation-perfusion -- CONCLUSION -- REFERENCES -- Chapter 3 DISCUSSION ON THE PATHOPHYSIOLOGICAL BASIS OF COPD -- Chapter 4 COPD AND SYSTEMIC INFLAMMATION: MYTH OR REALITY? REALITY -- ABSTRACT -- INTRODUCTION -- Origin of Systemic Inflammation in COPD -- Consequences of systemic inflammation in COPD -- CONCLUSION -- REFERENCES -- Chapter 5 COPD AND SYSTEMIC INFLAMMATION: MYTH OR REALITY? MYTH -- ABSTRACT -- INTRODUCTION -- GENERAL CONSIDERATIONS -- SMOKING AND 'SYSTEMIC INFLAMMATION' -- STABLE COPD AND 'SYSTEMIC INFLAMMATION' -- ACUTE EXACERBATIONS AND 'SYSTEMIC INFLAMMATION' -- THE EFFECT OF COPD TREATMENT ON 'SYSTEMIC INFLAMMATION' -- CONCLUSION -- REFERENCES -- Chapter 6 DISCUSSION ON COPD AND SYSTEMIC INFLAMMATION: MYTH OR REALITY? -- Chapter 7 BIOMARKERS OF SYSTEMIC INVOLVEMENT IN STABLE COPD: DO THEY EXIST? YES -- ABSTRACT -- INTRODUCTION -- PULMONARY BIOMARKERS IN STABLE COPD -- SYSTEMIC INVOLVEMENT IN COPD -- BIOMARKERS OF SYSTEMIC INVOLVEMENT IN STABLE COPD: MORE THAN SYSTEMIC INFLAMMATION -- BIOMARKERS OF SYSTEMIC INVOLVEMENT IN COPD: HOW TO PROGRESS? LESSONS LEARNED FROM HEART FAILURE -- BIOMARKERS OF SYSTEMIC INVOLVEMENT IN STABLE COPD: HOW TO PROGRESS? -- a. CC-16 -- b. Surfactant Protein D (SP-D) -- c. Cachexia -- d. Osteoporosis -- CONCLUSION. |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | REFERENCES -- Chapter 8 BIOMARKERS OF SYSTEMIC INOLVEMENT IN STABLE COPD: DO THEY EXIST? NO -- ABSTRACT -- INTRODUCTION -- Inflammation in COPD Concomitant Diseases -- The Role of "Inflammaging" -- Systemic Biomarkers Involvement in COPD -- The Controversial Meaning of Steroid Therapy in COPD -- Lung Specific Biomarkers in COPD: New Frontiers? -- CONCLUSION -- REFERENCES -- Chapter 9 DISCUSSION ON BIOMARKERS OF SYSTEMIC INVOLVEMENT IN STABLE COPD: DO THEY EXIST? -- Chapter 10 DISCUSSION IN-DEPTH OF TOPICS PRESENTED IN THE MORNING, WITH A VIEW TO REACHING A CONSENSUS OR DISSENSUS -- I. PATHOPHYSIOLOGICAL BASIS -- II. COPD AND SYSTEMIC INFLAMMATION: MYTH OR REALITY? -- III. BIOMARKERS OF SYSTEMIC INVOLVEMENT IN STABLE COPD - DO THEY EXIST? -- Chapter 11 BIOMARKERS OF SYSTEMIC INVOLVEMENT IN ACUTE EXACERBATIONS OF COPD: IS THERE OVERWHELMING EVIDENCE? YES -- ABSTRACT -- INTRODUCTION -- 1. WHAT IS AN EXACERBATION OF COPD? -- 2. WHAT IS A BIOMARKER? -- 3. SYSTEMIC INVOLVEMENT AT EXACERBATION OF COPD -- 4. WHAT DO WE WANT A SYSTEMIC EXACERBATION BIOMARKER TO ASSESS? -- 5. HOW SHOULD WE ASSESS THE EFFICACY OF A BIOMARKER IN ACHIEVING THESE AIMS? -- 6. A BIOMARKER TO CONFIRM EXACERBATION? -- 7. A BIOMARKER TO INFORM ON EXACERBATION AETIOLOGY? -- 8. A BIOMARKER TO INFORM ON EXACERBATION SEVERITY? -- 9. A BIOMARKER TO PREDICT POST-EXACERBATION EVENTS? -- CONCLUSION -- REFERENCES -- Chapter 12 IS THERE EVIDENCE FROM BIOMARKERS OF SYSTEMIC INVOLVEMENT IN COPD EXACERBATIONS? NO -- ABSTRACT -- INTRODUCTION -- a) Underlying Baseline Inflammation due to Comorbid Conditions -- b) Etiology of Exacerbations -- c) Impact of Treatment -- CONCLUSION -- REFERENCES -- Chapter 13 DISCUSSION ON: IS THERE OVERWHELMING EVIDENCE FROM BIOMARKERS OF SYSTEMIC INVOLVEMENT IN COPD EXACERBATIONS?. |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | Chapter 14 SCIENCE AT THE BEDSIDE. IS COPD A RESPIRATORY DISEASE WITH PROMINENT SYSTEMIC IMPLICATIONS OR A SYSTEMIC DISEASE WITH PULMONARY SYMPTOMS? COPD - A PRIMARILY RESPIRATORY DISEASE WITH IMPORTANT SYSTEMIC CONSEQUENCES -- ABSTRACT -- INTRODUCTION -- SYSTEMIC INFLAMMATION -- Acute Phase Proteins -- CRP -- COPD AND IMPAIRED FUNCTIONAL CAPACITY -- Pulmonary Factors -- Systemic Factors -- MUSCLE DYSFUNCTION AND MALNUTRITION IN COPD -- Mechanisms -- Treatment -- CARDIOVASCULAR DISEASE -- Coronary Artery Disease and Atherosclerosis -- Heart Failure -- Pulmonary Arterial Hypertension -- Cardiac Function at Rest -- Cardiac Function During Exercise -- Arterial Stiffness and Endothelial Function -- ANEMIA -- OSTEOPOROSIS -- Mechanisms -- Therapy -- DEPRESSION -- Mechanisms -- Treatment -- LUNG CANCER -- Mechanisms -- Therapy -- OBSTRUCTIVE SLEEP APNOEA -- IMPLICATIONS FOR THERAPY -- REFERENCES -- Chapter 15 SCIENCE AT THE BEDSIDE. IS COPD A RESPIRATORY DISEASE WITH PROMINENT SYSTEMIC IMPLICATIONS OR A SYSTEMIC DISEASE WITH PULMONARY SYMPTOMS? A CASE REPORT -- ABSTRACT -- CASE REPORT -- THE CASE FOR CONSIDERING COPD AS A SYSTEMIC DISEASE WITH PROMINENT RESPIRATORY MANIFESTATIONS -- Mrs. CG -- PROMINENT SYSTEMIC DISEASE AND PREDICTABLE CO-MORBIDITY IN COPD -- COPD AND SYSTEMIC INFLAMMATION -- An Inflammatory Respiratory Disease with Systemic Spill-over -- A Systemic Disease Involving Primarily the Lungs -- A Vicious Circle -- SYSTEMIC INFLAMMATION IN STABLE COPD -- SYSTEMIC INFLAMMATION AND ITS EFFECT ON THE TREATMENT OF MRS. CG -- SUMMARY -- REFERENCES -- Chapter 16 DISCUSSION ON: IS COPD A RESPIRATORY DISEASE WITH PROMINENT SYSTEMIC IMPLICATIONS OR A SYSTEMIC CONDITION WITH PULMONARY SYMPTOMS? -- Chapter 17 APPROACH TO COPD: RESPIRATORY OR SYSTEMIC TREATMENT? RESPIRATORY APPROACH -- ABSTRACT -- REFERENCES. |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | Chapter 18 APPROACH TO COPD: RESPIRATORY OR SYSTEMIC TREATMENT? SYSTEMIC APPROACH -- ABSTRACT -- INTRODUCTION -- COMPLEX CHRONIC COMORBIDITIES -- CLINICAL GUIDELINES FOR CORD AND CHRONIC DISEASES -- EFFECTS OF TREATMENT OF CORD ON ITS COMORBIDITIES -- Smoking Cessation -- Rehabilitation -- Supplemental Oxygen Therapy -- Pharmacologic Treatment -- EFFECT OF TREATMENT OF COMORBIDITIES ON COPD -- Statins -- -Blockers -- CONCLUSION -- REFERENCES -- Chapter 19 DISCUSSION ON THE APPROACH TO COPD: RESPIRATORY OR SYSTEMIC TREATMENT? -- Chapter 20 GUIDELINES AND CLINICAL PRACTICE: MYTH OR REALITY? - MYTH -- ABSTRACT -- INTRODUCTION -- MYTH 1: STEPWISE APPROACH TO TREATMENT OF COPD -- MYTH 2: SHORT-ACTING BRONCHODILATOR FOR MILD COPD -- MYTH 3: INHALED CORTICOSTEROIDS FOR SEVERE COPD -- TREATMENT OF COPD ACCORDING TO THE PATIENT CHARACTERISTICS -- THE REASON FOR THE CONFUSION -- CONCLUSION -- REFERENCES -- Chapter 21 GUIDELINES AND CLINICAL PRACTICE: MYTH OR REALITY? - REALITY -- ABSTRACT -- INTRODUCTION -- Source of Guidelines -- Methods -- Conflicts of Interest -- COPD GUIDELINES -- Reality or Myth -- Systemic Features and COPD Guidelines -- IMPACT OF GUIDELINES IN PATIENTS WITH CO-MORBIDITIES -- CONCLUSION -- REFERENCES -- Chapter 22 DISCUSSION ON: GUIDELINES AND CLINICAL PRACTICE: MYTH OR REALITY? -- Chapter 23 DISCUSSION IN-DEPTH OF TOPICS PRESENTED IN THE AFTERNOON, WITH A VIEW TO REACHING A CONSENSUS OR DISSENSUS -- IV. BIOMARKERS OF SYSTEMIC INVOLVEMENT IN ACUTE EXACERBATIONS OF COPD: IS THERE OVERWHELMING EVIDENCE? -- V. APPROACH TO COPD: RESPIRATORY OR SYSTEMIC TREATMENT? -- VI. GUIDELINES AND CLINICAL PRACTICE -- GOALS OF CLINICAL PRACTICE GUIDELINES -- PROBLEMS WITH CURRENT COPD GUIDELINES -- Chapter 24 SUMMING UP AND FINAL REMARKS -- INDEX. |
| 588 ## - SOURCE OF DESCRIPTION NOTE | |
| Source of description note | Description based on publisher supplied metadata and other sources. |
| 590 ## - LOCAL NOTE (RLIN) | |
| Local note | Electronic reproduction. Ann Arbor, Michigan : ProQuest Ebook Central, 2024. Available via World Wide Web. Access may be limited to ProQuest Ebook Central affiliated libraries. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Lungs -- Diseases, Obstructive. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Lungs -- Diseases, Obstructive -- Complications. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Inflammation. |
| 655 #4 - INDEX TERM--GENRE/FORM | |
| Genre/form data or focus term | Electronic books. |
| 776 08 - ADDITIONAL PHYSICAL FORM ENTRY | |
| Relationship information | Print version: |
| Main entry heading | Donner, Claudio F. |
| Title | COPD Is/Is Not a Systemic Disease? |
| Place, publisher, and date of publication | Hauppauge : Nova Science Publishers, Incorporated,c2009 |
| International Standard Book Number | 9781608760510 |
| 797 2# - LOCAL ADDED ENTRY--CORPORATE NAME (RLIN) | |
| Corporate name or jurisdiction name as entry element | ProQuest (Firm) |
| 830 #0 - SERIES ADDED ENTRY--UNIFORM TITLE | |
| Uniform title | Public Health in the 21st Century |
| 856 40 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://ebookcentral.proquest.com/lib/orpp/detail.action?docID=3019991">https://ebookcentral.proquest.com/lib/orpp/detail.action?docID=3019991</a> |
| Public note | Click to View |
No items available.